Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$3.05M
310.48K shares · 0.0% of portfolio
Ocular Therapeutix Inc
Ocular Therapeutix Inc (OCUL) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Bedford, United States and has 325 employees. The company is worth $1.45B. Revenue was $51.95M in fiscal 2025, down 18.5% from the year before. It reported a net loss of $265.94M. The share price is 59.8% below its 52-week high of $16.44. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $32.33M. In that quarter, 1 of them opened or added to the position and 4 reduced it. Over the last 30 days, company insiders sold $234.42K of its stock on the open market and bought none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +0.4% over 5Y.
today you would have $1,034.64▲ +3.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $12.14 | $8.54 | $4.46 | $2.81 | $6.97 | $20.70 | $3.95 | $3.98 | $4.45 | $8.37 | $9.37 | $23.52 | |
| P/S | 68.3x | 50.9x | 21.3x | 11.3x | 4.2x | 12.3x | 90.5x | 49.1x | 85.7x | 86.3x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PCRXPacira BioSciences, Inc. | $36.34 | 103.8x | 2.2x | 0.00% | 2.05% | $1.45B |
| KLRAKailera Therapeutics, Inc. | $11.25 | — | 1.3x | 0.00% | — | $1.46B |
| ETONEton Pharmaceuticals, Inc. | $50.31 | 125.8x | 30.5x | 0.00% | 35.97% | $1.44B |
| ANABAnaptysbio Inc | $48.10 |
| 127.6x |
| 132.5x |
| 652.5x |
| P/B | 6.1x | 4.0x | 4.3x | 7.3x | 6.2x | 6.1x | 20.7x | — | 4.8x | 6.3x | 4.6x | 2.6x | 8.6x |
| EPS | -$1.42 | -$1.22 | -$1.02 | -$0.97 | -$0.98 | -$2.56 | -$1.91 | -$1.57 | -$2.20 | -$1.80 | -$1.71 | -$2.69 |
| Profit margin | -1468.82% | -511.90% | -303.67% | -138.14% | -137.95% | -15.06% | -894.31% | -2043.34% | -3013.97% | -3296.20% | -2369.00% | -2271.31% | -3710.88% |
| ROE | -85.95% | -40.64% | -61.36% | -88.59% | -200.79% | -7.45% | -204.53% | — | -167.19% | -242.42% | -85.95% | -44.37% | -48.81% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 135.1x |
| 0.00% |
| — |
| $1.44B |
| AAPGAscentage Pharma Group International | $15.37 | — | 17.2x | 0.00% | -236.63% | $1.44B |
| INBXInhibrx Biosciences, Inc. | $97.10 | — | — | 0.00% | -1773.60% | $1.43B |